Lv1
30 积分 2026-05-09 加入
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
3天前
已完结
Aromatase Inhibitors in Breast Cancer
3天前
已完结
Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions
3天前
已完结
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5
4天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
4天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
4天前
求助中
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
4天前
已完结
Giredestrant plus Everolimus in Advanced Breast Cancer
4天前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
4天前
已完结
Overall survival with abemaciclib in early breast cancer
5天前
已完结